...MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was...
...MC2-01, its lead candidate, which uses the company’s PAD technology. MC2 said marketed formulations of calcipotriene/betamethasone...
...calcipotriene and betamethasone dipropionate that uses PAD technology Indication: Treat psoriasis Endpoint: Non-inferiority to Taclonex calcipotriene/betamethasone...

...MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was...
...MC2-01, its lead candidate, which uses the company’s PAD technology. MC2 said marketed formulations of calcipotriene/betamethasone...
...film of surfactants to encapsulate the oil phase, resulting in a stable cream formulation of calcipotriene/betamethasone...

...The U.K. approved Leo’s Enstilar calcipotriene/ betamethasone foam spray to treat plaque psoriasis in adults. In...
...procedure (see BioCentury, April 11). The aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene...
...synthetic corticosteroid, is marketed in the U.S. Leo Pharma A/S , Ballerup, Denmark Product: Enstilar calcipotriene/betamethasone...

...Leo said Enstilar calcipotriene/betamethasone received a positive outcome under EU’s decentralized procedure to treat plaque psoriasis...
...expects national approvals this year. The aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene...
...approved in the U.S. for the indication. Leo Pharma A/S , Ballerup, Denmark Product: Enstilar calcipotriene/betamethasone...

...faster readout," he said. Enstilar is an aerosol foam formulation of a fixed-dose combination of calcipotriene...

...FDA approved Enstilar calcipotriene/betamethasone to treat plaque psoriasis in patients ages >=18 years. Leo plans to...
...years. Leo plans to launch the aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene...
...betamethasone dipropionate, a synthetic corticosteroid, early next year. Leo Pharma A/S , Ballerup, Denmark Product: Calcipotriene/betamethasone...

...FDA and an MAA to EMA for Enstilar. Leo Pharma A/S , Ballerup, Denmark Product: Calcipotriene/betamethasone...
...Molecular target: Glucocorticoid receptor (GCCR) Description: Aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene...

...Leo Pharma submitted an NDA to FDA for calcipotriene/betamethasone dipropionate aerosol foam to treat psoriasis vulgaris...
...psoriasis vulgaris. The product is an aerosol foam formulation of a fixed-dose combination of 0.005% calcipotriene...
...and other countries this year and in 2016. Leo Pharma A/S , Ballerup, Denmark Product: Calcipotriene/betamethasone...

...Leo Pharma's Leo Pharma Inc. subsidiary launched Taclonex calcipotriene/betamethasone dipropionate to treat plaque psoriasis of the...
...treat plaque psoriasis of the scalp in patients 12-17 years old. The topical suspension containing calcipotriene...

...Kyowa launched Dovobet Ointment calcipotriene/betamethasone dipropionate in Japan to treat psoriasis vulgaris. Leo Pharma is responsible...